Frontlight ResearchEarly access
Ovarian cancer trials in China
185 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
- Where
- Anyang, Beijing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Shenyang, Tianjin, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 180
- Run by
- Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07042802 - Phase 1Taking peopleAPG-2449 in Patients With Advanced Solid Tumors
- Where
- Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Wuhan, Zhengzhou
- Age
- 18 years and over
- People
- 165
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT03917043 - Phase 1Taking peopleAPG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 90
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06687070 - Phase 3Not yet taking people in ChinaAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Zhanjiang, Zhengzhou
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - Phase 3Taking peopleA Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
- Where
- Shanghai
- Age
- 18 years and over
- People
- 450
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06994195 - Phase 2Taking peopleChemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 136
- Run by
- Bai-Rong Xia
See details and how to joinNCT07125391 - Phase 1Taking peopleA Study of DEG6498 in Participants With Solid Tumors
- Where
- Beijing, Guangzhou
- Age
- 18 years and over
- People
- 100
- Run by
- Degron Therapeutics Co.
See details and how to joinNCT07244835 - Phase 1Not yet taking people in ChinaIMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 19
- Run by
- Shanghai Gynecologic Oncology Group
See details and how to joinNCT07674615 - No phaseTaking peopleChemotherapy Supported by Autologous Hematopoietic Stem Cells
- Where
- Chongqing
- Age
- 18 years to 60 years
- People
- 40
- Run by
- Chongqing University Cancer Hospital
See details and how to joinNCT05401162 - Phase 3Not yet taking people in ChinaA Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
- Where
- Beijing, Kunming
- Age
- 18 years to 75 years
- People
- 404
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07545460 - Phase 2Not yet taking people in ChinaIparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer(Phase II)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 49
- Run by
- Obstetrics & Gynecology Hospital of Fudan University
See details and how to joinNCT07673835 - Phase 2Not yet taking people in ChinaA Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
- Where
- Beijing, Guangzhou
- Age
- 18 years and over
- People
- 30
- Run by
- Danatlas Pharmaceuticals Co., Ltd
See details and how to joinNCT07652073 - Phase 2Taking peopleAn Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Bai-Rong Xia
See details and how to joinNCT07667751 - Phase 2Not yet taking people in ChinaIparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Fudan University
See details and how to joinNCT07663513 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 178
- Run by
- Shenzhen Ionova Life Sciences Co., Ltd.
See details and how to joinNCT07610798 - No phaseTaking peopleRectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 300
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07616310 - Phase 1/2Taking peopleDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07617753 - Phase 2/3Taking peopleTrop2-targeted immunoPET Imaging of Solid Tumors
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 400
- Run by
- RenJi Hospital
See details and how to joinNCT06851663 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
- Where
- Shanghai
- Age
- 18 years and over
- People
- 201
- Run by
- Shenzhen Ionova Life Sciences Co., Ltd.
See details and how to joinNCT07612891 - No phaseTaking peopleClinical Application of PET Imaging Targeting MSLN in Malignant Tumors
- Where
- Wuhan
- Age
- 18 years to 65 years
- People
- 100
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06843629 - Phase 1/2Taking peopleJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
- Where
- Beijing, Guangzhou, Jinan, Shanghai, Shenyang, Zhengzhou
- Age
- 18 years and over
- People
- 144 worldwide
- Run by
- Jacobio Pharmaceuticals Co., Ltd.
See details and how to joinNCT06386146 - No phaseNot yet taking people in ChinaProspective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
- Where
- Wuhan
- People
- 1,000
- Run by
- Tongji Hospital
See details and how to joinNCT07593833 - Phase 1/2Taking peopleDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 42
- Run by
- Beijing Biotech
See details and how to joinNCT07589543 - No phaseTaking people18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 200
- Run by
- Peking University First Hospital
See details and how to joinNCT07557225 - No phaseNot yet taking people in ChinaA Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 500
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07586449